Efficacy and safety of transarterial chemoembolization combined with first-line tyrosine kinase inhibitors and programmed death-1 inhibitors for progressed hepatocellular carcinoma
Abstract:Background: After the failure of transarterial chemoembolization (TACE) combined with first-line tyrosine kinase inhibitor therapy, the subsequent therapy for progressed hepatocellular carcinoma (HCC) patients is still controversial. This study was performed to evaluate the safety and efficacy of the subsequent combination of PD-1 inhibitors (TACE combined with first-line tyrosine kinase plus PD-1 inhibitors) relative to switching to the subsequent regorafenib (TACE plus regorafenib).
Methods: The data of HCC … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.